Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations

AML with RUNX1-RUNX1T1 fusion is a WHO entity with a favorable outcome following intensive chemotherapy. The absence of RUNX1-RUNX1T1 transcripts in remission defines complete molecular response and correlates with a superior survival. However, a significant proportion of patients still relapses and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hemasphere
Autores principales: Höllein, Alexander, Nadarajah, Niroshan, Meggendorfer, Manja, Jeromin, Sabine, Kern, Wolfgang, Haferlach, Claudia, Haferlach, Torsten
Formato: Artigo
Lenguaje:Inglês
Publicado: Wolters Kluwer Health 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745937/
https://ncbi.nlm.nih.gov/pubmed/31723813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000178
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares